Corient Private Wealth
ANIK icon

Corient Private Wealth’s Anika Therapeutics ANIK Stock Holding History

Corient Private Wealth’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482K Sell
33,223
-31,225
-48% -$362K ﹤0.01% 2050
2025
Q4 		$619K Buy
64,448
+33,548
+109% +$321K ﹤0.01% 2184
2025
Q3 		$290K Buy
+30,900
New +$295K ﹤0.01% 2137

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Corient Private Wealth's ANIK Position: Q1 2026 in Review

Corient Private Wealth reduced its Anika Therapeutics (ANIK) stake by 48% in Q1 2026, selling an estimated $362K and leaving 33,223 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #2050.

Corient Private Wealth first reported a position in ANIK in Q3 2025 and has held it in 3 quarters since. The position peaked at $619K in Q4 2025. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Corient Private Wealth held 33,223 shares of Anika Therapeutics worth $482K as of Q1 2026.
  • Corient Private Wealth sold 31,225 Anika Therapeutics shares in Q1 2026, an estimated $362K.
  • Anika Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2050 holding.
  • Corient Private Wealth first reported a position in Anika Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Corient Private Wealth's Anika Therapeutics position peaked at $619K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.